首页|常规用药联合复方黄柏液治疗带状疱疹急性期的疗效观察

常规用药联合复方黄柏液治疗带状疱疹急性期的疗效观察

扫码查看
目的 探讨带状疱疹急性期采用常规用药联合复方黄柏液治疗的疗效.方法 回顾性分析 80 例带状疱疹急性期患者的临床资料,依据用药方法不同分为联合用药组和常规用药组,各 40 例.常规用药组给予患者常规用药治疗,联合用药组在常规用药组治疗基础上加用复方黄柏液治疗.比较两组患者皮损评分、疼痛强度(PPI)评分、视觉模拟评分法(VAS)评分、疼痛分级指数(PRI)评分、疼痛干扰睡眠评分(SIS评分)、临床疗效、不良反应发生情况、症状改善时间.结果 用药后,两组患者红斑面积评分、水疱簇数评分、水疱数量评分、水疱变化评分、皮损总分、PPI评分、VAS评分、PRI评分、SIS评分均低于用药前,且联合用药组患者红斑面积评分(0.35±0.08)分、水疱簇数评分(0.42±0.10)分、水疱数量评分(0.51±0.12)分、水疱变化评分(0.40±0.15)分、皮损总分(1.68±0.21)分、PPI评分(0.86±0.15)分、VAS评分(4.04±1.37)分、PRI评分(3.65±1.21)分、SIS评分(2.64±0.46)分均低于常规用药组的(1.05±0.12)、(1.12±0.13)、(1.24±0.23)、(1.21±0.11)、(4.62±1.02)、(2.05±0.33)、(4.66±0.95)、(5.14±1.23)、(3.90±1.14)分,差异显著(P<0.05).联合用药组治疗总有效率 95.00%(38/40)高于常规用药组的 75.00%(30/40),差异显著(χ2=6.275,P<0.05).联合用药组患者的药物不良反应发生率 10.00%(4/40)低于常规用药组的 32.50%(13/40),差异显著(χ2=6.050,P<0.05).联合用药组患者的止疱时间(6.26±0.97)d、结痂时间(8.02±0.85)d、脱痂时间(5.02±1.03)d、止痛时间(6.72±1.04)d、愈合时间(10.62±1.28)d均短于常规用药组的(8.00±0.76)、(11.76±1.17)、(8.02±1.03)、(8.35±1.12)、(13.30±2.61)d,差异显著(P<0.05).结论 带状疱疹急性期采用常规用药联合复方黄柏液治疗的疗效较常规用药治疗显著.
Efficacy observation of conventional medication combined with compound Huangbai solution in the treatment of acute stage of herpes zoster
Objective To explore the efficacy of conventional medication combined with compound Huangbai solution in the treatment of acute stage of herpes zoster.Methods Clinical data of 80 patients with acute stage of herpes zoster were retrospectively analyzed and divided into combined medication group and conventional medication group,each with 40 cases.The patients in the conventional medication group were treated with conventional medication,and the patients in the combined medication group were treated with compound Huangbai solution based on the conventional medication group.Comparison was made on skin lesion score,present pain intensity(PPI)score,visual analogue scale(VAS)score,pain rating index(PRI)score,sleep interference scale(SIS)score,clinical efficacy,occurrence of adverse reactions and symptom improvement time between the two groups.Results After medication,the erythema area score,vesicle cluster number score,vesicle number score,vesicle change score,total lesion score,PPI score,VAS score,PRI score and SIS score in both groups were lower than those before medication;in the combined medication group,the erythema area score was(0.35±0.08)points,the vesicle cluster number score was(0.42±0.10)points,the vesicle number score was(0.51±0.12)points,the vesicle change score was(0.40±0.15)points,the total lesion score was(1.68±0.21)points,PPI score was(0.86±0.15)points,VAS score was(4.04±1.37)points,PRI score was(3.65±1.21)points and SIS score was(2.64±0.46)points,which were all lower than(1.05±0.12),(1.12±0.13),(1.24±0.23),(1.21±0.11),(4.62±1.02),(2.05±0.33),(4.66±0.95),(5.14±1.23)and(3.90±1.14)points in the conventional medication group;the difference was significant(P<0.05).The total effective rate of the combined medication group was 95.00%(38/40),which was higher than 75.00%(30/40)of the conventional medication group,and the difference was significant(χ2=6.275,P<0.05).The incidence of adverse drug reactions in the combined medication group was 10.00%(4/40),which was lower than 32.50%(13/40)in the conventional medication group,and the difference was significant(χ2=6.050,P<0.05).In the combined medication group,the blister stopping time was(6.26±0.97)d,the scab formation time was(8.02±0.85)d,the scab removal time was(5.02±1.03)d,the analgesia time was(6.72±1.04)d,and the healing time was(10.62±1.28)d,which were shorter than(8.00±0.76),(11.76±1.17),(8.02±1.03),(8.35±1.12),and(13.30±2.61)d in the conventional medication group,and the difference was significant(P<0.05).Conclusion The treatment effect of conventional medicine combined with compound Huangbai solution in the treatment of acute stage of herpes zoster is more significant than that of conventional medicine.

Acute stage of herpes zosterCompound Huangbai solutionSkin lesion scoreAdverse drug reactionsSymptom improvement time

汪军喜、廖丽萍

展开 >

334000 上饶市皮肤病性病防治所

带状疱疹急性期 复方黄柏液 皮损评分 药物不良反应 症状改善时间

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(24)